People · Operator
Named in public records as an officer, director or promoter · active 2024–2024 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Reunion Neuroscience, Inc. | — | Pharmaceuticals | Series D+ | $119.8M | $1.5B | 2024 |
Mark Pollack at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mark Pollack on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Briggs Morrison | 1 | 8 |
| Ansbert Gadicke | 1 | 7 |
| Alon Lazarus | 1 | 7 |
| Robert Alexander | 1 | 6 |
| Michael Ehlers | 1 | 6 |
| Edward Smith | 1 | 5 |
| Gregory Mayes | 1 | 5 |
| Mark Theeuwes | 1 | 3 |
| Nathan Bryson | 1 | 3 |
| Ellen Lubman | 1 | 2 |
| Natalie Sacks | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.